Intranasal Covid vaccine manufactured by Hyderabad-based Bharat Biotech has been approved by the Drugs Controller General of India (DCGI) for restricted emergency use in individuals over the age of 18. This Covid-19 nasal vaccine is India’s first.
The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers, and no side effects have been reported, PTI reported.
As soon as the vaccine was approved on Tuesday, Union Health Minister Mansukh Mandaviya tweeted: Big boost to India’s fight against Covid-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against Covid-19 in the 18+ age group for restricted use in an emergency situation.
It was further stated that this step would strengthen “our collective fight” against the pandemic.
The product – iNCOVACC – is stable at 2-8°C, making storage and distribution easier. The company stated in its statement that it has established large manufacturing capabilities at multiple sites throughout India, including Gujarat, Karnataka, Maharashtra, and Telangana.
According to Dr. Krishna Ella, chairman and managing director of Bharat Biotech, INOVACC will revolutionize intra-nasal vaccine delivery systems. Despite low demand for COVID-19 vaccines, they continued to develop intra-nasal vaccines to ensure that we are well prepared for future infectious diseases, he added.
iNCOVACC has been evaluated to determine its safety impact, the company said, and it is designed for easy distribution and administration.
As a result of iNCOVACC, variant-specific vaccines can be developed faster and easy nasal delivery can be used to facilitate mass immunizations against emerging variants of concern. It promises to be an important tool for mass vaccinations during pandemics and endemics. In due course, the company said, the product will be launched and available for use.
Having a pre-fusion stabilized spike protein, NCOVACC is a recombinant replication-deficient adenovirus vectored vaccine. Phase-I, Phase-II, and Phase-III clinical trials of this vaccine candidate were successful, they added.
(This story has been sourced from a third-party syndicated feed, agencies. Raavi Media accepts no responsibility or liability for the text’s dependability, trustworthiness, reliability, and data. Raavi Media management/ythisnews.com reserves the sole right to alter, delete or remove (without notice) the content at its absolute discretion for any reason whatsoever.)
